AbbVie (ABBV) Total Liabilities (2012 - 2026)

AbbVie has disclosed Total Liabilities across 15 years of filings, most recently posting $143.1 billion for Q1 2026.

• In Q1 2026, Total Liabilities rose 6.25% year-over-year to $143.1 billion; the TTM figure through Mar 2026 stood at $143.1 billion (up 6.25% YoY), while the FY2025 annual figure was $137.2 billion, up 4.12% from the prior year.
• Total Liabilities advanced to $143.1 billion in Q1 2026, from $137.2 billion in the prior quarter.
• Over the last five years, Total Liabilities for ABBV reached as high as $143.1 billion in Q1 2026 and fell as low as $121.2 billion in Q1 2023.
• The 5-year median for Total Liabilities is $131.8 billion (2024), against an average of $131.1 billion.
• Annual changes were most pronounced in 2022 — Total Liabilities decreased 7.38% — and 2024, when it rose 16.15%.
• A 5-year view of Total Liabilities shows it stood at $121.5 billion in 2022, then advanced by 2.3% to $124.3 billion in 2023, then advanced by 6.02% to $131.8 billion in 2024, then rose by 4.12% to $137.2 billion in 2025, then increased by 4.29% to $143.1 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $143.1 billion, $137.2 billion, and $136.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.